Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
Key facts
- Where
- Bedford Park, Melbourne, New Lambton Heights, Perth, Southport, and Sydney, AustraliaSee the 6 sites
Where in Australia
- Flinders Medical Centre (Vascular Unit)Bedford Park, AustraliaContact: Melanie ToomeyTaking people
- The Alfred HospitalMelbourne, AustraliaContact: Adi ZiaTaking people
- John Hunter HospitalNew Lambton Heights, AustraliaContact: Natalie LottTaking people
- Royal Perth HospitalPerth, AustraliaContact: Jackie WongTaking people
- Gold Coast Hospital and Health ServicesSouthport, AustraliaContact: Cheryl RapierTaking people
- Royal Prince Alfred HospitalSydney, AustraliaContact: Lorna BeattieTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- W.L.Gore & Associates
- Trial code
- NCT06218875
- Record updated
- 12 November 2026
- Original description
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.Read full original descriptionShow less
Assessment of Long Term, Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.
Inclusion: Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements; Patient has been or is intended to be treated with an eligible registry device; Patient is age ≥ 18 years at time of informed consent signature.
Exclusion: Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol; Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures; Patient with exclusion criteria required by local law.